'On standalone basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of Sanofi India has declined 18.47% to Rs 419.80 crore. Operating profit margin has declined from 22.98% to 21.51%, leading to 23.67% decline in operating profit to Rs 90.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.94% to 14.13%. Purchase of finished goods cost fell from 39.34% to 31.80%. Employee cost increased from 8.87% to 11.42%. Other expenses rose from 15.34% to 19.59%.
Other income fell 52.54% to Rs 2.8 crore. PBIDT fell 25.04% to Rs 93.1 crore. Provision for interest up 50% to Rs 0.6 crore. Loan funds declined from Rs 19.30 crore as of 31 December 2024 to Rs 17.80 crore as of 31 December 2025. Inventories declined from Rs 499.80 crore as of 31 Dece...
Pleaselogin & subscribe to view the full report.
More Reports
-
(26-Feb-2026)
Foseco India
Net down 35% on higher EO Exp
-
(26-Feb-2026)
KSB
Net up 11%, sales up 8%
-
(25-Feb-2026)
Schaeffler India
Revenue jumps 28% and profit spurts 36% in Q4CY25
-
(25-Feb-2026)
Elantas Beck India
Net up 32% on good operating show
|
|